Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists
摘要:
A structure-based focused library approach was employed in an effort to identify more lipophilic replacements for the N-benzylpyroglutamyl group of the VCAM/VLA-4 antagonist 2. This effort led to the discovery of two new classes of potent antagonists characterized by the N-(alpha-phenylcyclopentanoyl- and the N-(2,6-dimethylbenzoyl)-derivatives 60 and 64. (C) 2002 Elsevier Science Ltd. All rights reserved.
Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists
摘要:
A structure-based focused library approach was employed in an effort to identify more lipophilic replacements for the N-benzylpyroglutamyl group of the VCAM/VLA-4 antagonist 2. This effort led to the discovery of two new classes of potent antagonists characterized by the N-(alpha-phenylcyclopentanoyl- and the N-(2,6-dimethylbenzoyl)-derivatives 60 and 64. (C) 2002 Elsevier Science Ltd. All rights reserved.
Compounds of the formula:
as well as their salts and esters are disclosed wherein X, X', Z, and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.
[EN] N-ALKANOYLPHENYLALANINE DERIVATIVES<br/>[FR] DERIVES DE N-ALCANOYLPHENILALANINE
申请人:——
公开号:WO1999010312A1
公开(公告)日:1999-03-04
[EN] Compounds of formula (1) as well as their salts and esters are disclosed wherein X, X', Z and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4. [FR] La présente invention concerne des composés représentés par la formule générale (1), ainsi que leurs sels et esters. En l'occurrence, X, X', Z et Y, qui sont conformes aux descriptions des spécifications de la présente demande, présentent une activité d'inhibition de la liaison entre le VCAM-1 et les cellules à expression de VLA-4. De tels composés conviennent pour le traitement d'affections dont les symptômes et/ou les atteintes sont en relation avec la liaison entre VCAM-1 et les cellules à expression de VLA-4.